Invention Grant
- Patent Title: Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
-
Application No.: US15546633Application Date: 2016-01-25
-
Publication No.: US11014989B2Publication Date: 2021-05-25
- Inventor: Julianne Smith , Julien Valton , Alexandre Juillerat , Philippe Duchateau , Barbra Johnson Sasu , Arvind Rajpal
- Applicant: Cellectis
- Applicant Address: FR Paris
- Assignee: Cellectis
- Current Assignee: Cellectis
- Current Assignee Address: FR Paris
- Agency: Casimir Jones, S.C.
- Agent Peter J. Schlueter
- Priority: DKPA201570044 20150126
- International Application: PCT/EP2016/051469 WO 20160125
- International Announcement: WO2016/120218 WO 20160804
- Main IPC: A61K35/17
- IPC: A61K35/17 ; C07K16/28 ; C07K14/725 ; C07K16/30 ; C12N5/00 ; C12N5/0783 ; A61K39/00 ; A61K39/395 ; C07K14/705 ; C07K14/735 ; G01N15/10 ; G01N15/14 ; G01N15/00
Abstract:
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.
Public/Granted literature
- US20180009895A1 ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (SCCARS) FOR CANCER IMMUNOTHERAPY Public/Granted day:2018-01-11
Information query
IPC分类:
